Oruka Therapeutics (ORKA) Assets Average (2011 - 2026)
Oruka Therapeutics' quarterly Assets Average came in at $496.5 million in Q1 2026, up 28.45% year-on-year from $386.6 million in Q1 2025, and little changed quarter-over-quarter from $498.9 million in Q4 2025.
Oruka Therapeutics has reported Assets Average for 16 years, with the latest figure at $496.5 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 28.45% year-over-year to $496.5 million; the trailing twelve-month figure through Mar 2026 stood at $496.5 million (up 28.45% YoY), and the FY2025 full-year result was $442.3 million, up 103.89% from the prior year.
- Assets Average for Q1 2026 stood at $496.5 million, roughly flat from $498.9 million in the prior quarter.
- The five-year high for Assets Average was $498.9 million in Q4 2025, with the low at $35.3 million in Q2 2024.
- Average Assets Average over 5 years is $190.6 million, with a median of $49.6 million recorded in 2022.
- Year-over-year, Assets Average declined 26.32% in 2022 and soared 951.48% in 2024.
- Tracing ORKA's Assets Average over 5 years: stood at $44.0 million in 2022, then declined by 12.5% to $38.5 million in 2023, then soared by 951.48% to $405.1 million in 2024, then rose by 23.18% to $498.9 million in 2025, then dropped by 0.48% to $496.5 million in 2026.
- The last three Assets Average figures came in at $496.5 million (Q1 2026), $498.9 million (Q4 2025), and $433.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 496.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 496.55 Mn |
| Dec 31, 2025 | 498.93 Mn |
| Sep 30, 2025 | 433.33 Mn |
| Jun 30, 2025 | 367.27 Mn |
| Mar 31, 2025 | 386.57 Mn |
| Dec 31, 2024 | 405.05 Mn |
| Sep 30, 2024 | 223.97 Mn |
| Jun 30, 2024 | 35.28 Mn |
| Mar 31, 2024 | 37.28 Mn |
| Dec 31, 2023 | 38.52 Mn |
| Sep 30, 2023 | 40.13 Mn |
| Jun 30, 2023 | 41.57 Mn |
| Mar 31, 2023 | 42.57 Mn |
| Dec 31, 2022 | 44.03 Mn |
| Sep 30, 2022 | 46.53 Mn |
| Jun 30, 2022 | 49.56 Mn |
| Mar 31, 2022 | 52.97 Mn |
| Dec 31, 2021 | 57.56 Mn |
| Sep 30, 2021 | 62.77 Mn |
| Jun 30, 2021 | 67.26 Mn |
| Mar 31, 2021 | 59.81 Mn |
| Dec 31, 2020 | 51.21 Mn |
| Sep 30, 2020 | 31.81 Mn |
| Jun 30, 2020 | 9.55 Mn |
| Mar 31, 2020 | 8.00 Mn |
| Dec 31, 2019 | 9.24 Mn |
| Sep 30, 2019 | 10.17 Mn |
| Jun 30, 2019 | 9.50 Mn |
| Mar 31, 2019 | 7.72 Mn |
| Dec 31, 2018 | 7.64 Mn |
| Sep 30, 2018 | 9.26 Mn |
| Jun 30, 2018 | 11.43 Mn |
| Mar 31, 2018 | 12.58 Mn |
| Dec 31, 2017 | 14.64 Mn |
| Sep 30, 2017 | 17.11 Mn |
| Jun 30, 2017 | 18.94 Mn |
| Mar 31, 2017 | 22.61 Mn |
| Dec 31, 2016 | 26.65 Mn |
| Sep 30, 2016 | 30.66 Mn |
| Jun 30, 2016 | 34.78 Mn |
| Mar 31, 2016 | 38.25 Mn |
| Dec 31, 2015 | 40.99 Mn |
| Sep 30, 2015 | 43.76 Mn |
| Jun 30, 2015 | 29.19 Mn |
| Mar 31, 2015 | 14.70 Mn |
| Dec 31, 2014 | 17.09 Mn |
| Sep 30, 2014 | 19.29 Mn |
| Jun 30, 2014 | 21.60 Mn |
| Mar 31, 2014 | 19.87 Mn |
| Dec 31, 2013 | 18.11 Mn |
| Sep 30, 2013 | 19.96 Mn |
| Jun 30, 2013 | 12.46 Mn |
| Mar 31, 2013 | 3.68 Mn |
| Dec 31, 2012 | 3.34 Mn |
| Sep 30, 2012 | 3.64 Mn |
| Jun 30, 2012 | 4.39 Mn |
| Mar 31, 2012 | 5.73 Mn |
| Dec 31, 2011 | 6.50 Mn |
| Sep 30, 2011 | 7.54 Mn |